⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CANF News
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
globenewswire.com
INCY
ACRS
TAK
AZN
PFE
GSK
JNJ
NVS
SNY
BHC
REGN
ABBV
ALGN
BMY
AMGN
ARCT
CANF
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
globenewswire.com
CANF
Pancreatic Cancer - Drug Pipeline Insight, 2026 | 170+ Companies and 200+ Therapies Signal Licensing, Investment, and Immuno-Oncology Growth Opportunities
globenewswire.com
MRKR
VRTX
ABUS
AGEN
IMUX
CANF
Metabolic Dysfunction-Associated Steatohepatitis Competitive Landscape and Clinical Trial Analysis Report 2026 Assesses 180+ Companies and 200+ Drugs
globenewswire.com
MDGL
NVO
GSK
ALT
GALT
VKTX
CRBP
CANF
BILI
MRK
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
globenewswire.com
CANF
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
globenewswire.com
CANF
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
globenewswire.com
CANF
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
globenewswire.com
CANF
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
globenewswire.com
CANF
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
globenewswire.com
CANF